NV-BELKIN
8.1.2024 02:01:33 CET | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today introduced four new products across its mobile power and connectivity portfolios, underscoring Belkin innovation, design excellence, dedication to quality, and commitment to building products more responsibly. Belkin is showcasing its newly announced products at CES Unveiled Las Vegas – the official media event of CES 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240107725407/en/
Belkin supercharges into CES 2024 with powerful new product lineup (Photo: Business Wire)
Charging in a snap with Qi2
BoostCharge Pro 3-in-1 Magnetic Stand
Leveraging the new Qi2 standard, this powerful 3-in-1 wireless charger offers perfect alignment and reliable charging for Qi2-enabled devices at 15W, fast charging for Apple Watch Series 7 and later, and optimal charging for wireless earbuds. Built to include an adjustable hinge, users can effortlessly adjust the angle of the phone for optimal viewing while watching videos, reading articles or video chatting. It is made with a minimum 75% post-consumer recycled (PCR) materials.
$149.99 USD
Coming March 2024 to select markets worldwide
BoostCharge Pro Magnetic Power Bank
The Qi2 magnetic power bank delivers up to 15W of power for Qi2-enabled devices on-the-go, without the hassle of cables. It is engineered with an integrated kickstand for propping the phone up while streaming, reading, or chatting, and works with magnetic and MagSafe cases up to 3mm thick. “Power pass-through” allows for charging the power bank and Qi2 device in one simple action via USB-C port. Offered in 5K, 8K and 10K options, consumers can choose the best power bank for their charging needs. Internal housing (excluding cable) of this product is made with a minimum 72% PCR materials.
$59.99, $79.99, $99.99 USD
Coming March 2024 to select markets worldwide
Power-packed and compact with GaN
BoostCharge Pro 4-Port USB-C GaN Charger 200W
The new 4-Port USB-C GaN Wall Charger packs an impressive 200W of power for fast charging up to 4 devices at the same time. It supports high powered laptops and gaming laptops and is engineered with GaN technology and Programmable Power Supply (PPS) to provide efficient power output and smart power allocation, giving connected devices a safe and optimal charge. The 4-Port USB-C GaN Wall Charger declutters the workspace while charging laptops, tablets, phones, smart watches and earbuds simultaneously – no extra power bricks needed. It is compact and power-packed, measured at 92mm x 118.5mm x 35.5mm, and 650g/1.32lbs. The housing (excluding power cord) of this product is made with a minimum 72% PCR materials.
$129.99 USD
Coming March 2024 to belkin.com and select markets worldwide
6-in-1 Core GaN Dock
Belkin is innovating its docks category with the use of GaN to deliver smaller, more efficient, more responsible workspace solutions. Approximately 50 percent smaller1 than other 6-in-1 solutions and highly spec'd to support all essential needs, the Core GaN Dock features 1x HDMI port for high-definition display resolutions up to 4K, 2x USB-A ports for legacy devices, 2x USB-C ports (1 with 96W power delivery), and 1 gigabit ethernet port for secure and reliable Internet connection.
$139.99 USD
Available to order now on belkin.com
Coming soon to select retailers worldwide
Built more responsibly
In line with the company’s commitment to find more responsible ways to build products, Belkin’s newly announced BoostCharge solutions are made with a minimum of 72% PCR materials and sold in plastic-free packaging. One year since Belkin announced its transition to PCR, it has transitioned over 200 products to incorporate PCR, and has replaced 64 metric tons of virgin plastic with PCR materials. Belkin remains committed to its goal of 100% carbon neutrality in its offices and operations (scope 1 & 2 emissions) by 2025 while tackling product level emissions (scope 3).
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From the humble beginnings of a garage in 1980s Southern California to a diverse, global technology company today, we remain forever inspired by the planet we live on, and the connection between people and technology.
1 Based on internal tests against competing non-GaN solutions with power supply unit. Dimensions: 80 x 80 x 48mm; surface area: 6,400mm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240107725407/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom